Epivir Hbv
Developed to mitigate active hepatitis B replication to support liver cell safety and target viral reverse transcription.
- Category
- Hepatitis Treatment
- Active ingredient
- Lamivudine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 100mg · 150mg
Prescription and consultation requirements for Epivir Hbv vary by destination and are determined by the fulfilment partner.
Epivir Hbv details
- Condition
- Chronic Hepatitis B Virus Infection
- Alternative names
- lamivudine
- Therapeutic class
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Pharmacological class
- Antiviral Agent
- Contraindications
- severe renal impairment; hypersensitivity to lamivudine
- Minor side effects
- headache; nausea; fatigue
- Moderate side effects
- elevated liver transaminases; abdominal pain; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- ViiV Healthcare
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Trimethoprim; Tenofovir
- Age restrictions
- Approved for children over two years and adults.
- Pregnancy and breastfeeding
- TGA Category C: Safe during pregnancy. Breastfeeding: Consult a clinician.
Serious side effects
lactic acidosis, requires immediate medical attention; severe acute hepatitis B flare, requires immediate medical attention
Patient summary
developed to mitigate active hepatitis B replication to support liver cell safety and target viral reverse transcription.
Mechanism of action
Incorporates into hepatitis B viral DNA to cause chain termination, slowing down the disease process in hepatocytes.